Respiratory syncytial virus (RSV) causes infections that range from common cold to severe lower respiratory tract infection that in some instances may have a fatal outcome. Especially infants, elderly and patients with underlying chronic disorders suffer from severe RSV infections[@b1][@b2]. In infants, RSV is the leading cause of lower respiratory tract infections (LRTI) and is responsible for 80% of acute bronchiolitis cases[@b3]. RSV infections pose a huge burden on society in terms of disease, logistics and socio-economic sequelae. There is an unmet need for an RSV vaccine, despite considerable research efforts no licensed vaccine has been developed.

In industrialized countries, 1--5% of infants with RSV infection are hospitalized[@b4][@b5][@b6][@b7]. Some of these infants yet suffer from severe disease upon admittance, while others are admitted without severe symptoms since the course of bronchiolitis is highly variable and the need for supportive care cannot be predicted[@b8][@b9]. Several risk factors for developing severe RSV disease in infants have been identified, including preterm birth, young age, sex and environmental factors like in-house smoking[@b10]. Notwithstanding these known risk factors, current medical practice does not allow accurate prediction of whether an infant will further progress to severe RSV disease or not and could even be sent home safely. Genomic technologies have contributed to study the virus-host interaction, including virus discovery, pathogenesis studies, the design of antiviral strategies and identification of biomarkers to support clinical management of infectious diseases[@b11][@b12][@b13][@b14]. For RSV infections, this has supported the characterization of vaccine-induced skewed host responses upon infection[@b15][@b16]. Meijas *et al*.[@b17] recently used blood transcriptome profiles obtained within 3 days of hospitalization to characterize the host response to RSV infection in infants compared with rhinovirus or influenza infections and identified transcriptional profiles that associate with RSV disease severity. However, a prognostic model for RSV severity based on gene expression profiles collected at admittance to the hospital has not been developed.

In this study we aim to identify and validate a gene signature that discriminates severe from less severe RSV LRTI that do not require advanced support. Such a signature together with other clinical parameters may improve the prognosis of less severe patients that could be safely sent home.

Material and Methods
====================

Study design
------------

Study subjects were recruited at Canisius Wilhelmina Hospital, Radboud University Medical Center, Nijmegen, and Erasmus Medical Center, Rotterdam, The Netherlands. Nasopharyngeal wash and blood samples were prospectively obtained from patients less than 2 years of age with a viral bronchiolitis. Patient enrolment occurred 7 days a week and samples were taken within 24 hours after first contact with the hospital. Seventy-three percent of all eligible bronchiolitis patients agreed to participate in the study. The major reasons for non-inclusion were parental availability to sign consent and the hesitancy for the venipuncture. Only patients with an RSV infection, as retrospectively determined by PCR were included in the study. Exclusion criteria were: immunodeficiency, systemic steroid treatment in the previous 2 weeks, blood transfusion, congenital heart and chronic lung disease. A Tempus tube (Tempus^TM^, Applied Biosystems, Austria) and sodium heparin tube were filled with 3 ml of blood. Medical history, demographic and clinical data were collected from medical records and questionnaires. The (hospitalized) patients were followed until recovery and were retrospectively classified as: mild for children without hypoxia, moderate for patients requiring supplemental oxygen (oxygen saturations \<90%, ≥10 minutes) and severe for children requiring mechanical ventilation due to apnea, exhaustion and/or respiratory failure. Recovery samples were obtained after 4--6 weeks, during home visits. Blood samples were obtained from healthy controls (HC) without underlying diseases or medication subjected to elective surgery.

Study approval
--------------

The study protocol was approved by the Regional Committees on Research involving Human Subjects of Arnhem-Nijmegen and Rotterdam and were conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from the parents of all children prior to inclusion in the study.

Sample processing and blood transcriptome profiling
---------------------------------------------------

Inclusion of patients and sample collection was performed by a single MD at the hospitals. Multiplex RT-PCR was performed to test the nasopharyngeal washes on 15 different viral pathogens, as previously described[@b18]. Blood was collected in Tempus tubes for immediate stabilization of RNA and subsequently stored at −80 °C. Total RNA was isolated from each blood sample, processed, assessed, labelled and hybridized to a single Affymetrix Human Genome U133 plus 2 gene chips; and image analysis was performed in the same lab and by one technician as described in [supplementary material](#S1){ref-type="supplementary-material"}. The raw data has been deposited in the ArrayExpress database under access number E-MTAB-5195.

Data preprocessing
------------------

Microarray data was preprocessed using R 3.1.2 [@b19] and Bioconductor[@b20]. Upon initial quality control and VSN normalization (to render samples comparable), probeset (a combination of multiple probes) summarization was performed by median polish[@b21][@b22]. Unless otherwise stated, all probesets/genes present on the Affymetrix GeneChip were used for data analysis. Samples were labelled and hybridized in two batches which did not correspond to any biological variable as samples were randomly assigned to the batches. The normalized expression values were adjusted for a batch effect (see [supplementary Fig. S1](#S1){ref-type="supplementary-material"}) using *ComBat*[@b23]. Additionally, we assessed confounding effects of clinical parameters age and sex on gene expression--severity relationship using "biasograms"[@b24].

Differential expression analysis
--------------------------------

To obtain a global view of the blood transcriptome changes in response to RSV infection (i.e. to evaluate whether whole transcriptome changes associate with severity), a principal component analysis (PCA) as an exploratory analysis was performed on the age by sex standardized data. Next, a differential expression (DE) analysis was performed on the normalized-batch-adjusted data controlling for an age by sex effect using empirical Bayes linear models[@b25] implemented in the R package *limma*[@b26]. Details of the models are found in [supplementary material](#S1){ref-type="supplementary-material"}. We controlled for multiple testing via false discovery rate (FDR) using a Benjamini and Hochberg procedure[@b27]. Gene set enrichment analysis was performed using Ingenuity pathway analysis (IPA, [www.qiagen.com/ingenuity](http://www.qiagen.com/ingenuity)).

Identification and evaluation of prognostic biomarkers
------------------------------------------------------

Since we are interested in identifying RSV-infected infants that will progress to severe stage upon presentation to the hospital, we grouped mild and moderate samples and aimed to separate these samples from infants that were presented with or progressed to severe disease after hospitalization. We chose to utilized probabilistic predictors (to predict the chance of an RSV-infected infant to be severe) because in clinical applications, probabilities are more informative than absolute yes or no predictions[@b28]. Several probabilistic predictors exist in the literature and their performance depends on the type of the data they are being applied on ref. [@b29]. Using results of ref. [@b29],[@b30] and observed correlations in the data, three probabilistic classification functions that could be optimal for this data were chosen as described in [supplementary material](#S1){ref-type="supplementary-material"}. These functions were support vector machines (SVM)[@b31], shrunken centroids discriminant analysis (SCDA)[@b32] and random forest (RF)[@b33].

For each classification function, the experimental data was split into a learning set and a test set using leave-one-out cross-validation (LOOCV). Cross-validation reduces optimistic bias by ensuring that our models are evaluated on an independent dataset that was not used to constructed these models. Most probabilistic classification functions require hyper-parameters to perform variable selection among the huge number of variables (probesets). Usually, the best values for these hyper-parameters are also determined by cross-validation. Thus, the parameter(s) of the function were optimized using an inner loop of five-fold cross-validation on the learning set. Next, a prognostic model was built with the optimal parameter(s) on the entire learning set and evaluated with the test set, as described in [supplementary material](#S1){ref-type="supplementary-material"}. The following R packages; *CMA*[@b34]*, e1071*[@b35], *pamr*[@b36] and *randomForest*[@b37] were utilized for class prediction. The best calibrated and refined function amongst the three functions was selected and its performance evaluated using the area under the receiver operating characteristic (ROC) curve (AUC). Finally, the transcripts that maximized the binomial log-likelihood function, with the leave-one-out cross-validated data were retained as a gene signature from the selected function as described in [supplementary material](#S1){ref-type="supplementary-material"}.

Comparison of biomarkers to clinical parameters
-----------------------------------------------

Age and sex are readily available clinical parameters that have been determined to be associated to RSV disease severity[@b38]. To assess the gain attained with a genomic model over a model with these clinical parameters, and the effect of standardization, the leave-one-out cross-validated predicted probabilities of progressing to severe for all samples were transformed to genomic scores (a genomic score is single measure of the genome of a sample as predicted by a model) for models with unstandardized and standardized data. Logistic regression models (see [supplementary material](#S1){ref-type="supplementary-material"}) were then fitted with the genomic scores and/or clinical parameters and their AUCs compared.

Validation of biomarkers
------------------------

For an independent validation, a subset of the Illumina RSV data of Meijas *et al*.[@b17] was used. Since the experimental data and validation data were obtained using different platforms, we linked the data using gene symbols and applied cross-platform transformation (to render gene expression comparable across datasets) as described in [supplementary material](#S1){ref-type="supplementary-material"}. The transformed data was supplied to our prognostic model for predictions of probabilities of severity. For a confirmatory analysis of how well our prognostic model performs, we built and evaluated a prediction model with the chosen function (same function used to build our prognostic model) on the entire Illumina data and compared our validation performance to the performance from this (unrestricted) data.

Results
=======

Study subjects and sampling
---------------------------

Thirty-nine infants hospitalized with acute RSV bronchiolitis were included in the study. Nasopharyngeal wash and whole blood samples for mRNA profiling were collected within 24 hours upon hospital admittance. [Table 1](#t1){ref-type="table"} presents the characteristics of the study subjects. As expected, patients with the most severe course of RSV bronchiolitis were significantly younger than those with a relative mild or moderate course of this disease. The variables related to disease severity; duration of oxygen, and length of stay in the hospital were highest in the severe group, with ventilation indicating the method by which oxygen was supplied. The proportion of co-infections was lower in severe patients as compared to the other severity categories. There were no differences in the occurrence of other known risk factors.

Age and sex as confounders of gene expression--severity relationship
--------------------------------------------------------------------

[Figure 1a,b](#f1){ref-type="fig"} respectively illustrate the confounding effects of sex and age on the gene expression-disease severity relationship. These figures show that whereas age is negatively correlated to severity, sex is uncorrelated to severity. Nevertheless, the high positive/negative correlations of a considerable number of transcripts to sex and age, as well as severity, indicate a confounding effect of these variables on the expression-severity relationship of these transcripts, thus warrant adjustment. [Figure 1d,e](#f1){ref-type="fig"} illustrate the "biasograms" after an age by sex standardization. These figures show that standardization has no effect on severity correlated transcripts but as expected, transcripts that were originally correlated to age and sex become uncorrelated. A positive correlation of age to sex which signifies an age by sex interaction as a potential confounder on the gene expression-severity relationship was also observed ([Fig. 1c](#f1){ref-type="fig"}) and eliminated after standardization ([Fig. 1f](#f1){ref-type="fig"}).

Global blood transcriptome profiles associate with RSV disease severity
-----------------------------------------------------------------------

[Figure 2](#f2){ref-type="fig"} illustrate a PCA on the whole transcriptome and the first principal component accounts for 25% of the variance in the transcriptomes and associates with disease severity. Transcriptome profiles of HC and recovery samples group together on the first principal component and are located opposite to profiles of severe infants. The distinct groups do not form discrete clusters in the PCA but gradually shift from mild through moderate to severe, with considerable overlap. This shows that the blood mRNA profiles substantially capture the severity of lower respiratory tract RSV infection.

Number of differential gene expression relates to RSV disease severity
----------------------------------------------------------------------

[Table 2](#t2){ref-type="table"} presents results of differential gene expression analysis and reveals that the number of DE transcripts increases with disease severity. No DE transcript was identified between mild versus HC samples when applying a FDR of 5% and absolute fold change (FC) threshold of 2. However, 17 and 221 transcripts were DE between moderate and severe versus HC respectively. Interestingly, all transcripts that are DE in moderate class are also DE in severe class with larger FC. About 90% of these DE transcripts are up-regulated. Comparison of HC with recovery samples revealed a single down-regulated transcript while moderate versus mild yielded no DE transcript, severe versus mild or moderate yielded 178 and 49 DE transcripts respectively. Lastly, 95 transcripts were DE between severe versus combined mild/moderate samples.

RSV induced blood transcriptome profiles reveal an inflammatory response
------------------------------------------------------------------------

[Figure 3](#f3){ref-type="fig"} shows that multiple relevant categories of molecular and cellular functions are significantly enriched when comparing severe to HC samples. With "Cell-to-Cell Signaling and Interaction" top category, gene sets related to activation of several types of immune cells including lymphocytes, granulocytes and specifically neutrophils are most significantly enriched. In addition, gene sets that are involved in migration and tissue infiltration of these same activated cell types are most significantly enriched within the category "Cellular Movement" that ranks third on this figure. Finally, several high ranking molecular and cellular function categories and their underlying gene sets indicate the immune cells involved are strongly proliferating. A list of genes involved in each of these pathways is presented in [supplementary Table S1](#S1){ref-type="supplementary-material"}. Taken together, blood transcriptome changes in RSV disease reveal a typical inflammatory response to a viral infection.

Early blood transcriptome changes to predict a severe outcome of RSV infection
------------------------------------------------------------------------------

To construct a predictive model, we combined mild and moderate cases as a single group and three probabilistic classification functions were chosen based on [supplementary Fig. S2](#S1){ref-type="supplementary-material"} and results of Jong *et al*. and Kim and Simon[@b29][@b30]. Using these functions, classifiers were built and evaluated using LOOCV on the experimental data. SVM was chosen as the best calibrated and refined as shown on [supplementary Fig. S3](#S1){ref-type="supplementary-material"} and henceforth considered for all analyses. The LOOCV predicted probabilities from SVM were used to evaluate its performance and are plotted on [Fig. 4a](#f4){ref-type="fig"} against the true RSV status as retrospectively determined. This figure shows that 5 samples out of 39 were misclassified at a 50% cutoff and when applying a proposed uncertainty band of 30--70% just one false negative is witnessed. Evaluation of the clinical characteristics of the single false negative patient as well as those patients with uncertain predictions (plotted within the proposed uncertainty band) did not reveal any recognizable pattern. The false negative patient had uniquely RSV and only a single patient plotted within the uncertainty band had RSV+ other virus(es). [Figure 4b](#f4){ref-type="fig"} presents the corresponding ROC curve from the LOOCV predicted probabilities and AUC of 0.966 demonstrates the high discriminative power of our prognostic model.

Genomic biomarkers outperform clinical parameters age and sex
-------------------------------------------------------------

[Figure 4c](#f4){ref-type="fig"} presents the ROC curves from logistic models of clinical parameters and/or genomic scores. The genomic score model from the standardized data (AUC = 0.966) outperforms that from the unstandardized data (AUC = 0.915). In addition, there is a significant difference between a model with age and sex only (AUC = 0.833) and that with a standardized (AUC = 0.966) or unstandardized genomic score (AUC = 0.915). Whereas there is a slight improvement from clinical parameters and standardized genomic score model (AUC = 0.971), there is no improvement from the clinical parameters and unstandardized genomic score (AUC = 0.911), indicating that indeed standardization completely removed an age-by-sex effect on the gene expression data.

An 84 gene expression signature predicts absence of disease progression
-----------------------------------------------------------------------

To extract the prognostic signature, we selected top transcripts maximizing the binomial log-likelihood function using LOOCV predicted probabilities as illustrated on [supplementary Fig. S4](#S1){ref-type="supplementary-material"}. This figure depicts a 1-SE maximum of 95 transcripts corresponding to 84 unique genes, which are displayed on [Table 3](#t3){ref-type="table"}. Of the 95 transcripts constituting the prognostic signature, 81 (85.26%) were found to be significantly DE between severe and non-severe patients (FDR cutoff of 5%, [supplementary Table S2](#S1){ref-type="supplementary-material"}). The inclusion of non-DE transcripts in the classification model is expected, since not only DE genes are instrumental in class discrimination as illustrated by the two-dimensional scenario in [supplementary Fig. S5](#S1){ref-type="supplementary-material"}.

Performance of the genomic signature retained on an independent dataset
-----------------------------------------------------------------------

For an independent validation, a subset of the Illumina RSV data of Meijas *et al*.[@b17] was used. Since the experimental data and validation data were obtained using different platforms, we linked the data using gene symbols and applied cross-platform transformation (to render gene expression comparable across datasets) as shown on [supplementary Fig. S6](#S1){ref-type="supplementary-material"} and extensive described in the [supplementary material](#S1){ref-type="supplementary-material"}. [Figure 5a](#f5){ref-type="fig"} presents predicted probabilities of severe on the validation data using 75 of our 84 prognostic gene signature that were common in both experimental and validation datasets, while [Fig. 5b](#f5){ref-type="fig"} presents the LOOCV predicted probabilities from SVM on the entire Illumina data. Both figures show that using the unrestricted data leads to more certain probabilities and slightly improves specificity compared to our signature. Nonetheless, [Fig. 5c](#f5){ref-type="fig"} illustrates a large agreement between the predicted probabilities of the two models, while [Fig. 5d](#f5){ref-type="fig"} clearly reveals that both models are alike as demonstrated by the AUCs of 0.858 and 0.856 for our signature and the unrestricted model respectively. To assess the concordance of the expression patterns of our signature on both datasets (Affymetrix and Illumina), we plotted the log~2~ fold changes of the common 75 genes as shown on [Fig. 6](#f6){ref-type="fig"}. From this figure, one clearly sees that there is a huge concordance in the direction of expressions across datasets. Where there are slight differences, these differences are not significant as shown by a non-significant p-value in at least one of the datasets.

Discussion
==========

RSV infection in infants may cause life-threatening disease. No vaccine is yet available and triage of patients is challenging since RSV infections may rapidly progress to severe disease. No reliable prognostic model to predict which RSV patient will not progress to severe disease and could be safely send home is available either. Thus, clinical care is symptom-based and a significant proportion of RSV infected infants is hospitalized for observation purposes. We have provided an 84 gene signature that discriminates hospitalized infants with less severe RSV infection from those infants with severe RSV disease. The identified signature yielded a LOOCV AUC of 0.966 on the experimental data and was independently validated with an AUC of 0.858 and might serve as a basis to develop a prognostic test for clinical management of RSV disease.

In line with epidemiological observations[@b38] and observations of Mejias *et al*.[@b17], we showed the confounding effects of age and sex on gene expression-severity relationship for RSV disease. Studies in any RSV patient cohort with a naturally occurring "skewed" distribution of age and sex can be standardized for these parameters. By adjusting for an age-by-sex effect in our analyses, we obtained age-by-sex independent results which can be effectively applied to any patient(s). The high performance of our signature on the age and sex matched validation data signifies age-by-sex independence and robustness of this signature. Fewer co-infections were observed in severe patients ([Table 1](#t1){ref-type="table"}). A similar trend has been described previously[@b39]. In our cohort study we did not take into account co-infections since no consistent association between the occurrence or absence of co-infections with RSV disease severity have been reported[@b39][@b40][@b41][@b42][@b43]. Furthermore, we aimed at the identification of a gene signature in a natural "real-life" cohort of patients not stratified according to age or occurrence of co-infections.

We hypothesized that changes in blood cell type distribution and/or mRNA expression changes of the circulating cells collected from peripheral blood reflect local lung host response characteristics that associate with disease severity. PCA and DE analysis indeed revealed significant changes in the transcriptome profile of whole blood. Gene set analysis further shows that relevant processes are monitored including the activation, migration and tissue infiltration of lymphocytes, granulocytes and neutrophils. Individual DE genes in severe RSV disease revealed overexpression of the neutrophil associated genes MMP8 and MMP9, which have previously been related to severe RSV disease[@b44]. ARG1 and CHI3L1 that have been linked to alternatively activated macrophages in a mouse model for vaccine enhanced RSV disease[@b16] were also found to be strongly up-regulated. This suggests that the collected blood transcriptome profiles indeed reflect local lung host response.

In our class prediction analysis, three functions were evaluated and the best was chosen. While it has been pointed by[@b45][@b46][@b47][@b48] that selecting a minimal-error classifier leads to selection bias that should be corrected, the literature does not stipulate a selection bias when using calibration and refinement scores as evaluation measures. Nevertheless, we employed the nested cross-validation correction of selection bias[@b46] in our model building procedure by splitting our experimental data into learning and test sets with an inner loop split on the learning set for parameter(s) optimization. Though found to contain high variance, we utilized leave-one-out cross-validation for the test set because it yields approximately an unbiased estimate of the true (expected) prediction error[@b49] and because we were interested in the individual sample predicted probability of severe and not entirely on the expected predicted error. Nevertheless, where we were interested in the expected predicted error, as in the optimization of parameters, we utilized five-fold cross-validation as recommended by Breiman and Spector[@b50]. To validate the identified signature, an independent dataset generated on a different platform was used. Despite (i) the several sources of variability between our experimental data and the validation data that stem from - but not limited to - array platforms and different clinical cutoffs of RSV severity statuses, (ii) different time of profiling, 1--3 days after hospitalization and (iii) loss of information due to a reduction in signature because of no corresponding transcripts on Illumina platform and the aggregation of multiple transcripts to genes, our signature yielded an AUC of 0.858 that was comparable to accuracy (AUC of 0.856) when using the Illumina data (validation set) as experimental set. Cross-platform validation is rare due to lack of guidance on how this can be done reliably. We presented a cross-platform validation procedure.

The RSV patients enrolled in the study displayed varying disease severities but were all hospitalized thus representing a severe disease enriched subset of RSV infected infants. The patients enrolled however also represent a natural cohort of patients including a significant number of patients that eventually did not require extensive medical care and could have been discharged home. Since the blood samples were collected soon after hospital admission, the generated blood transcriptomes and the derived gene signature may serve as a basis for the development of a novel genomic tool to support clinical management of RSV disease including triage of patients presenting at the hospital provided that a rapid (real time) gene test can be developed. Larger transcriptome data sets are however required to construct predictive models that may also allow for discriminating mild from moderate and moderate from severe cases. Ultimately, one would like to extend the RSV biomarker program to earlier time point samples (e.g. obtained when visiting a general practitioner) and to samples collected from patients infected by other (respiratory) infectious agents or pathological conditions (comorbidities) in order to identify specific respiratory viral prognostic biomarkers. To this end a novel gene signature have to be developed using a much larger early blood sample cohort. The current results support the development of diagnostic tests for personalized medicine that not only provide information on the causative infectious agent, but also about the disease severity that may be expected.
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![Confounding effect of Sex, Age and Age by Sex on gene expression--severity relationship, before.\
(**a,b,c**) and after: (**d,e,f**), an age by sex standardization. The blue and green lines represent the clinical variables, the cosine of the angle between the lines represents its correlation to the blue line (Sex is not correlated to Severity, Age is negatively correlated to Severity i.e. younger kids become severe and Age is positively correlated to sex i.e. females are older). The cloud of points represent the transcripts and their correlations to both variables with most transcripts uncorrelated to the variables (yellow cloud) while a considerable number (black cloud) are correlated to Severity, Sex, Age and Age \*Sex. The associations between the transcripts and Sex, Age or Age \*Sex are significantly eliminated after standardization while retaining that of Severity.](srep36603-f1){#f1}

![Global blood transcriptome profiling with principal component analysis: the first principal component (PC1) accounts for 25% of the variance in the dataset and associates with disease severity.\
This can be observed as a shift from healthy controls and recovery cases (left) through mild and moderate to severe cases (right), with considerable overlap.](srep36603-f2){#f2}

![Ingenuity pathway analysis (IPA) Molecular and Cellular functions gene set analysis for severe vs healthy control contrast.](srep36603-f3){#f3}

![Internal validation of gene signature.\
(**a**) samples' predicted probabilities of being severe. (**b**) shows the ROC curve and the AUC for predicted probabilities. The AUC value of approximately 1 indicates how accurate our signature performs on this internal validation set. (**c**) shows that a genomic model from the age by sex standardized data out performs that from the unstandardized data. In addition, there is a significant difference between a model with clinical parameters and that with a genomic score and just a slight improvement when both parameters are included in a model.](srep36603-f4){#f4}

![Predicted probabilities of being severe from the validation data against true RSV status using; our diagnostic signature (**a**) and LOOCV on unrestricted data (**b**). (**c**) illustrates the agreement of the predictions from both models, green regions are perfect agreement, blue are disagreements at a 50% cutoff and red are disagreements at a 30--70% uncertainty band. Finally, (**d**) presents the ROC curves and AUC from both models illustrating similar AUC values.](srep36603-f5){#f5}

![Log~2~ Fold change between Severe vs Non-Severe infants for 75 common genes in Affymetrix and Illumina datasets.\
Red represent up-regulation while green represents a down-regulation and the significant FDR adjusted p-values are placed in the cells. As one can clearly see, there is a huge overlap in the direction expressions across datasets. Where there are slight differences, these differences are not significant as shown by a non-significant p-value in at least one of the datasets.](srep36603-f6){#f6}

###### Patient characteristics (n represents the number of samples per group).

  Parameters                Mild (n = 7)       Moderate (n = 14)   Severe (n = 18)
  ------------------------- ------------------ ------------------- ------------------
  Age (days)                153 \[84, 291\]    185 \[60, 333\]     31 \[17, 76\]
  Gestational age (weeks)   40 \[29, 41\]      40 \[37, 41\]       39 \[37, 40\]
  Birth weight (kg)         3.5 \[3.0, 4.2\]   3.4 \[3.1, 3.9\]    3.3 \[2.5, 4.0\]
  Symptomatic days          4 \[2, 6\]         4 \[3, 6\]          3 \[2, 4\]
  Duration on O~2~ (days)   0                  3 \[2, 5\]          8 \[7, 11\]
  Ventilation               None               Supplemental        Mechanical
  Length of stay (days)     4 \[2, 6\]         5 \[3, 8\]          11 \[9, 13\]
  Breastfeeding             4 (57)             11 (79)             12 (67)
  Male gender               5 (71)             10 (71)             12 (67)
  RSV + other virus(es)     4 (57)             8 (57)              3 (17)

Data are presented as median and interquartile range (IQR) in square brackets \[.\] or number and percentage in brackets ().The median age of the healthy controls was 536 days (IQR \[472, 602\]).

###### Number of differentially expressed transcripts for each contrast at FDR of 5% and absolute fold change cutoff of 2.

           Mil-HC   Mod-HC   Sev-HC   Mod-Mil   Sev-Mil   Sev-Mod   RC-HC   Sev-(Mil+Mod)/2
  ------- -------- -------- -------- --------- --------- --------- ------- -----------------
  UP         0        15      194        0        164       42        0           82
  Down       0        2        27        0        14         7        1           13
  Total      0        17      221        0        178       49        1           95

Where Mil: Mild, Mod: Moderate, Sev: Severe, HC: Healthy controls (\<2years) and RC: Recovery samples.

###### Gene signature of 95 transcripts (probesets) corresponding to 84 genes.

  N^[o]{.ul}^   Affymetrix IDs                        Gene Symbol   Illumina IDs
  ------------- ------------------------------------- ------------- -------------------------------------------------------------------------------------------------------------------
  1             1553605_a\_at                         ABCA13        0pf.QRwb4sWsn7jQKQ
  2             238439_at 239196_at                   ANKRD22       oXed_glbkhVEMCDCTo xnW5awXa6P_EbICH0s HIf_t7qU.BejlFP86o
  3             209369_at                             ANXA3         orojh4FCCMN1ArUY6k
  4             205678_at                             AP3B2         9SneFS4fUDnuF7_nVM
  5             206632_s\_at                          APOBEC3B      9Ff619hplIXH7nOK6I
  6             206177_s\_at                          ARG1          0lVMTIuod_g0ohAnFE
  7             232197_x\_at                          ARSB          3IDh9IVCveAqVdCl2o cMniVI7195NdYNUqeo BJIKm4IFqJ01E3eHp4 0u0lM7OqfU.quOIC94
  8             201242_s\_at                          ATP1B1        unu3iN6N5U0f6cuEqc 9pU2OJP.BMdTLf9e64 fvOfs_Dnt_E3fl_11o
  9             214575_s\_at                          AZU1          QBuHuFVihS7ZVBBu5E
  10            221530_s\_at                          BHLHE41       EUN35CXUp3p.txedvU
  11            205557_at                             BPI           EqRaeX9VKg13UjfBQg
  12            210244_at                             CAMP          rItcu7lcV6dKfep3iA
  13            209498_at 211889_x\_at                CEACAM1       KpCYUm43RIkQFdLdQU fr.cFeEaHuTH9XTU54 xKXCKf3Uoo8n6L3cx0
  14            203757_s\_at 211657_at                CEACAM6       9criZPiUuucDnEx1B4
  15            206676_at                             CEACAM8       ubtBVA.8bOI1.LUVDo
  16            209395_at 209396_s\_at                CHI3L1        Zn_tzf4mVHIVHodF1U
  17            208168_s\_at                          CHIT1         NA
  18            220496_at                             CLEC1B        uSC2Dit6C6ijp2vN0g
  19            208146_s\_at                          CPVL          cdfjqToegKNUoMQgpI ZeEuC6evE1pCauH1NI
  20            210262_at                             CRISP2        ukOTfdVSNNEgNH9KQ4
  21            207802_at                             CRISP3        uqDXiAQ0SFE4hwohO4
  22            205653_at                             CTSG          0RKUnUS75SJfDAbUSI
  23            202859_x\_at                          CXCL8         3Vy3nJSjUQtfvUe5fo EVLftPlJ7vrLnu_Dxo
  24            207269_at                             DEFA4         6530r9KdBCqTred_SM
  25            206871_at                             ELANE         NtF0nlRFRHdSTekQwE
  26            224225_s\_at                          ETV7          9KCUpFjIkVJVFXsDoM
  27            213506_at                             F2RL1         BSHqBKlSg3u6xAXk64 ZAl9Iq.oUTd.oAy.kE
  28            211734_s\_at                          FCER1A        WgUoCn0h94FRNcJQFU
  29            231093_at                             FCRL3         KV7kDSLO4uggquLXB4 ZUclXxUi6VEoBJeRT8 67unrLpPnjv_uzOezU
  30            205110_s\_at                          FGF13         Hd7t51A7ISQ_3qyhSc Hvun37sCEoHuge477c TmCOYpTxe.jV7aAXpE
  31            223836_at                             FGFBP2        xmX900n31irhK4CFXE
  32            223767_at                             GPR84         ok0Fe53OSU4FlD1lCQ
  33            210321_at                             GZMH          rgmXcEkpOIcF9d6l4U
  34            206647_at                             HBZ           lteivVSVR8WbDmUMBQ
  35            213537_at                             HLA-DPA1      NFtdNMC3eb3pThValQ
  36            203290_at                             HLA-DQA1      NA
  37            209480_at                             HLA-DQB1      TfXanqXzTU0Si0gKnU
  38            206697_s\_at                          HP            fpPOCkkS1WAIIRYIlc
  39            215118_s\_at                          IGH           NA
  40            212592_at                             IGJ           HhecR84SAQucRJ7rVE
  41            217148_x\_at                          IGLC1         NA
  42            234764_x\_at                          IGLV1-44      NA
  43            227140_at                             INHBA         cp0iOCS4CISg_oqAqI
  44            206494_s\_at 206493_at 216956_s\_at   ITGA2B        H3o0v7nktkZOvQbtdU
  45            212531_at                             LCN2          WUTbfV7VDYUuzYaeLk
  46            208450_at                             LGALS2        WT6GkkHqpCBBqCNF7k
  47            222196_at                             LOC389906     NA
  48            238717_at                             LOC441528     NA
  49            1569110_x\_at                         LOC728613     NA
  50            202018_s\_at                          LTF           cQO5fddUoFsfScd65c
  51            244523_at                             MMD           6p_X8jaueM_Xv1yw6k
  52            207329_at 231688_at                   MMP8          fgvcFUrFTg7ifFKt.k BelT8r_h3KIiQoopKI
  53            203936_s\_at                          MMP9          fn3Hpm4vVouL4FK6FA
  54            203949_at 203948_s\_at                MPO           KXq9Q16d7p_cnO4×4k
  55            229510_at                             MS4A14        QqQF0qheQ0ghuCkj.Q 0JYKEkJ0rogLlAHvOU
  56            210254_at 1554892_a\_at               MS4A3         lKdKj.P0uB56B0ROV4 Qen_rt.er1_QxUxR9Q B3q9A94B7R88Xs4E6k
  57            201058_s\_at                          MYL9          Tbs1URA5CdFCtV3S1U 3CBVEhgxeipOOJilWo
  58            209290_s\_at                          NFIB          BNHPXrzdFBgpyimm0g QUlzHnJJ50×5LQ8egk
  59            221690_s\_at                          NLRP2         EFIl20d6F6tINX6rcs
  60            206343_s\_at                          NRG1          ruNF5QODCEECIJIKkI EX0VFaBXiuIGVC0kHQ rcTUUeoQlN_wDuaIKI 9QpESNQOTkjUnNJB00 uX15cu4f_VUIuXoST0 ZZlmuuNioCuRWSaaSQ
  61            212768_s\_at                          OLFM4         rgjyBSHxwUPUVVFBVc c70LXLcyj6S.A5.HVU
  62            210004_at                             OLR1          9V0C7RDnXXjh11UgBQ
  63            205040_at                             ORM1          fG6ilCJP2dH5410qEU
  64            227474_at                             PAX8-AS1      NA
  65            225207_at                             PDK4          ESC1yEuE.fDrqLUnTk
  66            207384_at                             PGLYRP1       3mxHd1KQUncUXTUg_k
  67            41469_at 203691_at                    PI3           NeHlSg0ILnuCnfmo6U
  68            207341_at                             PRTN3         EX243qjuUVl.1eH30Y
  69            211748_x\_at 212187_x\_at             PTGDS         HXlUBYwuThoEModVKk
  70            220570_at                             RETN          Qz8qQwkk_l6LlIm0XU
  71            206851_at                             RNASE3        9aLI9auX8dR7hdMDUo
  72            213566_at                             RNASE6        Te4VV0giY1VcQvr17E
  73            214539_at                             SERPINB10     f0LQV4ks6o4uOX0lAk
  74            1553177_at                            SH2D1B        0TlE1O9_rTf.5×9Oi0
  75            219519_s\_at                          SIGLEC1       iiFGSdPjXjklE7iF0E
  76            220000_at                             SIGLEC5       Q13VUdxtx69ahqiNUw oJC4o.lSL0tenoolEk
  77            203021_at                             SLPI          No174RVAVBCigl6guU
  78            202286_s\_at                          TACSTD2       WihIT5WgHS3Pz30n5U
  79            205513_at                             TCN1          i4uimBR4lCiesvG_1k
  80            209651_at                             TGFB1I1       EJXHlJXn14J32nhJWc iJVfHqoq1_Q9SYNopQ
  81            219410_at                             TMEM45A       6qievf0j6P7Xs1VS6I r_iBJ6cKOHcLse.k.U
  82            206641_at                             TNFRSF17      iWCth3hT5.UdUnOigo
  83            218876_at                             TPPP3         ENZUufqUJFe6TUJ1Xo QLe5eyXThVBUlUpOnA
  84            231122_x\_at                          ZDHHC19       69eJXi6CX97l_V.lR0

[^1]: These authors contributed equally to this work.
